Key takeaways:

• Senator Herb Kohl, Chairman of the Senate Subcommittee on Antitrust, Competition Policy and Consumer Rights, has alerted the Federal Trade Commission to possible deficiencies in prescription drug availability, urging the Commission to analyze the effect of future pharmaceutical mergers on competition.
• We expect increased antitrust scrutiny of prospective mergers of pharmaceutical companies, at least over the near term.